1. Home
  2. MSGS vs PRAX Comparison

MSGS vs PRAX Comparison

Compare MSGS & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Madison Square Garden Sports Corp. (New)

MSGS

Madison Square Garden Sports Corp. (New)

HOLD

Current Price

$332.76

Market Cap

8.2B

ML Signal

HOLD

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$341.29

Market Cap

9.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MSGS
PRAX
Founded
1879
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Services-Misc. Amusement & Recreation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.2B
9.6B
IPO Year
2015
2020

Fundamental Metrics

Financial Performance
Metric
MSGS
PRAX
Price
$332.76
$341.29
Analyst Decision
Buy
Strong Buy
Analyst Count
9
15
Target Price
$326.29
$572.13
AVG Volume (30 Days)
182.0K
374.8K
Earning Date
05-04-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.52
$6,395.88
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$184.63
$34.89
52 Week High
$345.48
$354.87

Technical Indicators

Market Signals
Indicator
MSGS
PRAX
Relative Strength Index (RSI) 57.91 58.92
Support Level $303.92 $282.49
Resistance Level $335.08 $353.83
Average True Range (ATR) 8.53 16.82
MACD 0.38 3.40
Stochastic Oscillator 58.02 77.98

Price Performance

Historical Comparison
MSGS
PRAX

About MSGS Madison Square Garden Sports Corp. (New)

Madison Square Garden Sports Corp owns and operates a portfolio of assets featuring some of the recognized sports teams, including the Knicks of the NBA and the Rangers of the NHL. It generates revenue from several sources: ticket sales and a portion of suite rental fees at The Garden and others. It has one operating and reportable segment and one reporting unit for goodwill impairment testing purposes.

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Share on Social Networks: